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Quantitatively describing the time course of the SARS-CoV-2 infection within an 
infected individual is important for understanding the current global pandemic 
and possible ways to combat it. Here we integrate the best current knowledge 
about the abundance of potential SARS-CoV-2 host cells and typical 
concentrations of virions in bodily fluids to estimate the total number and mass 
of SARS-CoV-2 virions in an infected person. We estimate that each infected 
person carries 10​9​-10​11​ virions during peak infection, with a total mass of about 1 
μg-0.1 mg, which curiously implies that all SARS-CoV-2 virions currently in the 
world have a mass of only 0.1-1 kg. Knowledge of the absolute number of virions 
in an infected individual can put into perspective parameters of the immune 
system response, minimal infectious doses and limits of detection in testing.  
  
Estimating key biological quantities such as total number and mass of cells in our body 
or the biomass of organisms in the biosphere in absolute units helps develop a deep 
quantitative perspective and improves our intuition and understanding of the living world 
(Moran et al. 2010;​ ​Sender et al. 2016a;​ ​Sender et al. 2016b; ​ Bar-On et al. 2018) ​. Such 
a quantitative perspective could help the current intensive effort to study and bring 
under control the COVID-19 pandemic by clarifying a myriad of key numbers such as 
minimal infectious doses and limits in testing. We have recently compiled quantitative 
data at the virus level as well as at the community level to help communicate 
state-of-the-art knowledge to both the public and researchers and provide them with a 
quantitative toolkit to think about the pandemic ​(Bar-On et al. 2020) ​. Here we leverage 
such quantitative information to estimate the total number and mass of SARS-CoV-2 
virions present in an infected individual during the peak of the infection. 
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Viral concentrations and viral particles are being measured in several different ways 
resulting in great differences in values and their meanings. Here, we report our 
estimates in two ways. First via viral RNA copies, as they are measured by RT-PCR, 
and representing the amount of viral RNA produced, including defective and deactivated 
virions. The second way is by infectious virions, excluding the defective and deactivated 
virions, measured in units of fifty-percent tissue culture infective dose (TCID50) by virus 
titer (endpoint dilution assay quantifying the amount of virus required to kill 50% of 
infected host cells). Thus, we try to estimate both the total amount of viral particles 
through RNA copies and the number of infectious virions through TCID50 
measurements. 
 
To estimate the total number of virions present in an infected individual at the peak of 
the infection, we rely on several studies which measured the concentration of virions 
(measured in genome copies per gram tissue) in tissues of rhesus macaques, after 
infections with SARS-CoV-2 ​(Munster et al. 2020​; Williamson et al. 2020)​.The viral 
concentrations were analyzed for samples of all the relevant tissues of the respiratory, 
digestive and immune systems, and were given per gram of tissue. An estimate for the 
total number of virions can be obtained from these measurements by multiplying the 
viral concentration of each tissue by the total tissue mass ​(ICRP 2002; ​ Snyder et al. 
1975)​. The lungs are the largest tissue in terms of mass ( ≈1kg) and had theM lungs  
highest viral concentration ( ) and thus contribute the most to the overall estimate,C lungsvirions  
with 
 
C lungsvirions                   N ×  M lungs                            =  virions       (1) 
.0 0 [ ]1 6 − 1 8 g
RNA copies ×  [kg] 000 [ ]1 × 1 gkg 0 0  [RNA copies]= 1
9 − 1 11  
 
Other tissues, like the nasal mucosa, larynx, bronchial tree and adjacent lymph nodes 
all have a combined mass of ~100g and maximal concentrations of 10​6​-10 ​7​ RNA 
copies/ml and hence contribute at most an additional 10% to the estimate based on the 
lungs (Figure 1).  
 
Another study ​(Rockx et al. 2020)​ measured the viral concentrations in tissues taken 
from infected rhesus macaques, a few days after inoculation. However, this study 
reports its values in units of TCID​50 ​which give an assessment of the concentration of 
infectious viruses. The study reports much smaller maximal values of 10​3​-10 ​4​ TCID​50​/ml 
for lung tissue. Combining their concentration with the volume of an adult human lungs, 
we get an estimate of 10​5​-10 ​7​ TCID​50​ virions in an adult, compared with 10​9​-10 ​11 ​RNA 
copies, estimated from ​(Munster et al. 2020)​(Figure 1). This large difference appears to 
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be representative of the use of viral titers instead of viral loads, as a similar difference of 
4-5 orders of magnitude is observed in bronchoalveolar lavage fluid measurements in 
rhesus macaques by ​(Williamson et al. 2020)​ and in nasopharyngeal swabs taken from 
454 human participants ​(Quicke et al. 2020)​. 
 
Based on this line of evidence, we estimate the total number of virions in an infected 
individual during peak infection at 10​9​-10 ​11​ RNA copies, or 10 ​5​-10 ​7​ TCID​50​. 
 
Figure 1: A schematic representation of the estimate of the number of virions in an infected 
individual. The estimate is made using the concentrations of virions measured in a gram of 
rhesus macaque tissue multiplied by the mass of human tissues. 
 
 
Calculating the total number of cells infected with SARS-CoV-2 
We can leverage our estimate of the total number of virions in the body of an infected 
individual to estimate the size of the population of cells which are infected with the virus 
during peak infection. As shown in Figure 2, to estimate the total number of infected 
cells, we need to know how many virions are found within each infected cell.  
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In order to determine the number of virions within an infected cell at any given time we 
rely on several lines of evidence. The first is data regarding the burst size of other 
betacoronaviruses (as we are not aware of measurements for SARS-CoV-2). The burst 
size is defined as the total number of viruses produced by an infected cell (the yield) 
throughout its lifetime, in analogy with bacterial lytic infections. Two previous studies 
suggested virion yield of either 10-100 or 600-700 infectious virions (in Plaque Forming 
units  - PFUs) ​(Robb and Bond 1979; ​ ​Hirano et al. 1976) ​. The time scale that is relevant 
for this yield is a few days ​(Chu et al. 2020)​. Thus, we can assume that by the first 
estimate at any given moment there are few to tens infectious virions that reside in each 
infected cell, and tens to hundreds of infectious virions by the second. The second line 
of evidence concerns the density of viral particles, within a single cell. Several studies 
have used transmission electron microscopy (TEM) to characterize the dynamics of viral 
infection within cells ​(Imai et al. 2020; ​Kim et al. 2020; ​ ​Klein et al. 2020;​ ​Ogando et al. 
2020)​. Using seven TEM scans taken from those studies we estimated that the density 
of viral particles within infected cells is 10​5​ viral particles per 1 pL. As the human cells 
targeted by SARS-CoV-2 have a volume of ≈1 pL (resulting in a cellular mass of ≈1 ng) 
(Stone et al. 1992; ​ Crapo et al. 1982)​, the TEM scans indicate the at a given moment 
there are ≈10 ​5​ viral particles within a single cell. Those viral particles include defective 
virions, and as we saw earlier, it is reasonable to assume that only 1 in 10​4​ of them is 
infective. Thus TEM scans indicate that ≈10 infectious virions reside inside a cell in a 
given moment. We can perform a sanity check using mass considerations to see that 
our estimate of the number of viral particles is not beyond the maximal amount that is 
feasible. Each viral particle has a mass of  ≈1 fg ​(Bar-On et al. 2020) ​. Hence, 10 ​5​ viral 
particles weigh ≈0.1 ng, about 10% of the total mass of the cell (and more than a third of 
its dry weight). That means that it is not reasonable to assume that there are more than 
10 ​5​ viral particles or 10 infectious virions within a cell at any given moment. Following 
those lines of evidence we conclude that at a given moment there are ≈10 infectious 
virions residing inside a cell, and that the overall yield of an infected cell is 10-100 
infectious virions over a few days. 
  
     Y virions per cell
N infectious virions = N infected cells   (2)  
.0 0  [cells]10[ ]cellvirions
10 −10 [virions]5 7 = 1 4 − 1 6  
 
How does this estimate stack up against the number of potential host cells for the virus? 
The best-characterized route of infection for SARS-CoV-2 is through cells of the 
respiratory system, specifically the pneumocytes (a total of about ~10​11 ​cells in the 
body), alveolar macrophages (~10​10 ​cells) and the mucus cells in the nasal cavity (~10​9 
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cells) ​(Stone et al. 1992; ​ Crapo et al. 1982)​. Other cell types, like enterocytes (gut 
epithelial cells) can also be infected ​(Lamers et al. 2020)​. Our best estimate for the size 
of the total potential pool of host cells is thus ~10​11​ cells, and the fraction of cells 
infected during peak infection therefore represents a small fraction of this potential pool 
(1 in 10 ​5​-10 ​7​).  
 
 
Figure 2: Estimation of the number of infected cells and their fraction out of the potential 
relevant host cells.  
 
Virion production rate and the total number of virions produced throughout an 
infection  
In addition to analyzing the state of an infected individual during peak infection, we can 
also ask what is the total number of virions produced over the course of an infection, as 
well as what is the rate of virion production inside a human host. First, in order to 
estimate the total number of virions produced during an infection, we rely on the 
average number of viruses an infected cell yields, which is about 10-100 (based on 
measurements from different kinds of betacoronavirus ​(Robb and Bond 1979;​ ​Hirano et 
al. 1976)​, and our estimate of the number of virions within a single cell at any given 
moment). The total number of virions produced over the course of an infection can be 
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estimated by multiplying the burst size by the total cumulative number of infected cells 
as 
             NN cells ×    Y virions per cell =  
︿
total virions throughout disease         (3) 
0 0 [cells] 0 00[ ]   10 0  [infectious virions, TCID50]1 4 − 1 6 × 1 − 1 cell
virions =  5 − 1 8   
 
This value exceeds the peak number of virions we estimated by about an order of 
magnitude. In terms of RNA copies, this translates into 10​9​-10 ​12​ RNA copies. 
 
In order to estimate the rate of production of virions we divide the burst size by the 
duration it takes the infected cells to produce that burst size, known to be a few days 
(Bar-On et al. 2020) ​. We thus estimate that each infected cell produces ~10 infectious 
virions per day on average. To estimate the maximal production rate for all infected 
cells, we multiply this production rate per single infected cell by the 10​4​-10 ​6​ infected 
cells. Thus the maximal production rate of virions is given by:  
       N           Q  P cells ×  virions per cell per day =  virions per day       ​ (4) 
.0 0 [cells] 0 [ ]             10 0  [ ]1 4 − 1 6 × 1 virionscell×day =  
5 − 1 7 day
infectious virions (TCID50)  
 
While the estimates were performed using a reference value for the lung mass taken 
from adult men, they can be generalized for women and children. We rely on the 
multiplication of the viral concentration in the lungs and the total mass of the lungs. 
Reference values for the lung mass show a value smaller by 20% for women, and 
75%-25% for children aged 5-15 years ​(ICRP 2002)​. Although COVID-19 is known to 
affect adult men more than women and children ​(Salje et al. 2020;​ ​WHO 2020) ​, there is 
scarce information regarding difference in viral concentrations across gender and age. 
One preprint ​(Jones et al. 2020)​ suggests that viral concentration in children is lower by 
up to an order of magnitude, but the change they measured is not consistent across the 
entire age range. Assuming the change in measured viral load represents a similar 
change in viral concentration in the lung tissue, and combining the concentrations with 
the reduced lung mass, we get that the number of virions in an infected woman is 
similar to that estimated for men, and that an infected child is probably carrying an order 
of magnitude less virions. 
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Discussion 
To provide some context for our estimate of the total number of virions per infected 
individual, we can compare it with the total of 3x10​13​ human cells in the body ​(Sender et 
al. 2016b)​. We find that even for the higher end of the range of estimates for viral 
particles there is still a 10-100 factor in favor of the human cells. A more functional 
comparison is with the number of antibodies the body produces to combat the viral 
infection. Total IgG antibody levels specific for SARS-CoV-2 spike protein( ) wereC IgG  
measured 3 weeks  following symptom onset showing a concentration in the serum on 
the order of  ~10 𝜇g/mL ​(Iyer et al. 2020) ​. Only a fraction of ≈5% of the total anti-spike 
IgG antibodies has the capacity to neutralize the virus ( ) ​(Rogers et al. 2020)​.f neutralizing  
Combining the concentration of neutralizing IgG antibodies with a mean IgG molecular 
weight ( ) of 150 kDa ​(Janeway et al. 2001)​ we can derive the number ofMW IgG  
neutralizing antibody molecules in an mL of serum( ):N
︿
neutralizing  
          f                            C IgG ×  neutralizing × 1MW  IgG × NAvogadro   =  N
︿
neutralizing        (5) 
.0 [ ] % [ ] [ ] 0 [ ] 0 [ ]1 −5 mL
g IgG × 5 IgG
neutralizing × 1150,000 g
mol × 6 × 1 23 mol
molecules = 3 × 1 12 mL
neutralizing molecules   
Combining this estimate with the measurement of viral concentration within the lung 
tissue ​(Munster et al. 2020)​ and ​accounting for 30-40 spike trimers on each 
SARS-CoV-2 virion (​Yao et al. 2020​,​ Turoňová et al. 2020 ​) we can estimate the ratio of 
neutralizing antibodies to viral spike proteins:  
     R
 N
︿
neutralizing   
            C               × Nlungsvirions spike proteins
=  neutralizing antibodies/spike proteins      (6) 
    10 0 [ ]. 3×10 [ ] 
12
mL
neutralizing  molecules
10 −10 [ ]  ×     30            6 8 mL
viral particles =  3 − 1 5 spike protein
neutralizing antibodies  
 
Previous work on morphologically similar viruses such as influenza and flavivirus found 
that a ratio of 1 neutralizing antibody to 2-4 receptor-binding proteins was sufficient to 
neutralize binding of a virion to its cellular receptor ​(Taylor et al. 1987; ​ ​Pierson and 
Diamond 2015)​. Taken at face value, our estimate seems to suggest an excess of 
neutralizing antibody molecules, even if we consider that the antibodies concentrations 
30-in the lung tissue is lower than that of the blood, and the extensive glycosylation 
patterns found on the spike protein that shield many of its epitopes ​(Turoňová et al. 
2020)​ from neutralizing antibody binding and thus decrease the efficiency of 
neutralization ​(Schön et al. 2020)​. However, it is important to remember that in order to 
estimate the effectiveness of antibody neutralization, we need to estimate the fractional 
occupancy of the viral epitopes by antibodies. This fractional occupancy is determined 
by the strength of the binding of the neutralizing antibodies to the viral particles, given 
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by the dissociation constant K​d ​(Pierson and Diamond 2015)​. Following the first order 
relation:  
raction bound by nAb  f =  [nAb][nAb] + Kd        ​(7) 
As the dissociation constants are mostly in the range of 1-10 nM ​(Chi et al. 2020​; 
Seydoux et al. 2020)​ we get: 
      (8)  
nAb] 3 0 [ ] [ ] 1000 [ ] 0 [ ] 3 [nM ] [ =  × 1 12 mL
neutralizing molecules × 1
6×1023
mol
molecules ×  L
mL = 3 × 1 −9 L
mol =    
raction receptors bound by nAb 5% 5%f =  3 [nM ]3 [nM ] + 1−10 [nM ] = 2 − 7  
Thus, the concentration of antibodies is needed to ensure that enough of the epitopes 
are bound, regardless of the high ratio between the number of neutralizing antibodies 
and viral particles.  
 
The total number of virions and their tissue concentration can also shed some light on 
the mechanism of action of antiviral drugs, such as Remdesivir. In their study with 
rhesus macaques ​(Williamson et al. 2020)​ measured a median concentration of ≈3 nmol 
of the activated drug within 1 gram of homogenized lung tissue, after six days of 
treatment. This is equal to 2x10​15 ​molecules per 1 gram of tissue, about 7-8 orders of 
magnitude more than the concentration of virions within the tissue. It appears that this 
ratio of antiviral drug to viral concentration is needed as the reported concentrations are 
also close to the measured EC50 (50% effective concentration) of ≈10 𝜇M ​(Choy et al. 
2020)​. 
 
One can contextualize these estimates using an absolute mass perspective. Each virion 
has a mass of  ≈1 fg ​(Bar-On et al. 2020) ​. Therefore even when the body carries 
10 ​9​-10 ​11​ viral particles, these have a mass of only about 1-100 μg, i.e. 1-100 times less 
than the mass of a poppy seed. Taking a global view across all of humanity and 
assuming a total of 10-100 million infected people at a given time (including the 
undetected), we arrive at a total mass of all the virions residing in humanity to be on the 
order of 0.1-1 kg. Furthermore, using the total number of viral particles produced 
throughout an infection (10​9​-10 ​12​ per person) we can derive the total mass of all the 
SARS-CoV-2 viral particles ever produced throughout this current pandemic. Assuming 
the total number of infected people actually will be 1 billion people we find the total 
mass of viral particles produced for such widespread infection to be on the order of 
 
(9)             N infected people × M viral particle × N viral particles produced per person      = M all viral particles  produced  
.0 [people] 0 [ ] 0 0 [ ] 000 kg1 9 × 1 −15 gviral particle × 1
9 − 1 12 person 
viral particles produced = 1 − 1  
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We have shown how our estimate for the total number of virions could be used to 
estimate currently unknown quantities such as the fraction of potential host cells that are 
infected during peak infection. Single-cell RNA-sequencing studies ​(Sungnak et al. 
2020​; Zeigler et al. 2020​; Lukassen et al. 2020)​ indicate that a few percent of the cells in 
the lungs and airways express ACE2 (angiotensin-converting enzyme 2) and TMPRSS2 
(Transmembrane protease, serine 2), the receptor and main protease SARS-CoV-2 
relies on for infecting cells. Most of the cells that have been found to express both are 
type 2 pneumocytes. While these results might be biased due to drop-out effects in 
measurements of only a few molecules ​(Valyaeva et al. 2020​; Zeigler et al. 2020)​, it is 
still reasonable that 1%-10% of the lung and airway cells contain the necessary receptor 
to be infected by SARS-CoV-2. This number is several orders of magnitude higher than 
our estimate for the total number of infected cells during peak infection -  a fraction of 1 
in 10 ​5​-10 ​7 ​of the​ ​potential lung cells. This suggests that out of the cells expressing both 
ACE2 and TMPRSS2, only a small fraction, e.g. 10​-3​-10 ​-5​, get infected by the virus. 
 
There is very high variability in viral loads, exceeding 5 orders of magnitudes, as can be 
seen from samples taken from the upper respiratory system ​(Jacot et al. 2020) ​. This 
wide variation reflects the difference between people as well as differences in viral load 
through the progression of infection within an infected individual ​(He et al. 2020)​. In our 
estimates we consider only a smaller range of viral concentration, corresponding to the 
center of the distribution of the measured values (interquartile range - between the 
quantiles 25%-75%). Thus, extreme cases could exceed the range provided by 
additional two orders of magnitudes, reaching values of 10​13​ viral particles in a single 
person at the peak of infection, while up to 10% of the cells expressing both ACE2 and 
TMPRSS2 are infected. 
 
Major knowledge gaps that we identified are the virion yield per infected cell which is 
known only from a few studies on different kinds of betacoronavirus from over 40 years 
ago ​(Robb and Bond 1979;​ ​Hirano et al. 1976) ​. 
 
The global impact of SARS-Cov-2 is clearly evident from its influence on public health 
and the global economy. Contrasting these global effects with the very moderate 
cumulative mass of these viruses highlights the limits of our day-to-day intuition in 
understanding and combating this pandemic and the need to rely on sound quantitative 
information rather than gut feelings. Having better quantitative information on the 
process of infection at the cellular level, the intra-host level and the inter-host level will 
hopefully empower researchers with better tools for thinking about ways to combat 
COVID-19 and curb its spread and that of future pandemics. 
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